Juan Silva, MD
Family Medicine · Los Angeles, CANPI 1790738110
Payments from drug & device makers
Across 436 payments — averaging $29.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Boehringer Ingelheim$880
- Corcept Therapeutics$865
- Novo Nordisk$850
- Lilly USA, LLC$653
- Pfizer$562
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$3,00023%
- Food & beverage$9,78176%
- Education$600%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $4,756 |
| Boehringer Ingelheim | 39 | $880 |
| Corcept Therapeutics | 29 | $865 |
| Novo Nordisk | 45 | $850 |
| Lilly USA, LLC | 30 | $653 |
| Pfizer | 26 | $562 |
| Abbott | 24 | $555 |
| Merck | 22 | $502 |
| Johnson & Johnson | 25 | $461 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $409 |
| AstraZeneca | 17 | $369 |
| Amgen(2 entities) | 10 | $205 |
| Boston Scientific | 1 | $156 |
| Medtronic(2 entities) | 4 | $143 |
| Xeris Pharmaceuticals, Inc. | 7 | $140 |
| Sanofi Pasteur Inc. | 7 | $139 |
| Sanofi-aventis U.S. LLC | 6 | $130 |
| Novartis | 5 | $111 |
| Amarin Pharma, Inc. | 5 | $96 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $91 |
| Exact Sciences | 3 | $82 |
| Radius Health, Inc. | 3 | $81 |
| GSK | 3 | $77 |
| Bayer | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $51 |
| Gilead | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $47 |
| Phadia US Inc. | 2 | $31 |
| Zealand Pharma US, Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Lundbeck LLC | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Alk-abello, Inc | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Cequr Corporation | 1 | $13 |
| Breathe Technologies, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$3,125
- Korlym$244
- XIFAXAN$213
- WATCHMAN FLX$156
- FREESTYLE LIBRE 3$150
- Creon$108
- CoreValve Evolut$100
How this compares
$12,841 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 296 | $354,703 |
| OzempicSemaglutide | 272 | $299,252 |
| CreonLipase/Protease/Amylase | 56 | $110,248 |
| FarxigaDapagliflozin Propanediol | 80 | $94,160 |
| EliquisApixaban | 73 | $78,355 |
| RybelsusSemaglutide | 34 | $66,024 |
| JanuviaSitagliptin Phosphate | 46 | $55,896 |
| RexultiBrexpiprazole | 21 | $38,518 |
| MounjaroTirzepatide | 37 | $36,165 |
| LinzessLinaclotide | 28 | $35,227 |
| XareltoRivaroxaban | 34 | $34,836 |
| TrulicityDulaglutide | 28 | $28,600 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $25,327 |
| EntrestoSacubitril/Valsartan | 16 | $22,118 |
| VascepaIcosapent Ethyl | 29 | $19,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Spiriva Respimat | $880 | $402,674339 claims |
| Novo NordiskOzempic, Rybelsus | $850 | $365,275306 claims |
| AbbVieCreon, Linzess | $4,756 | $145,47484 claims |
| AstraZenecaFarxiga | $369 | $94,16080 claims |
| PfizerEliquis | $562 | $78,35573 claims |
| Lilly USA, LLCMounjaro, Trulicity | $653 | $64,76465 claims |
| MerckJanuvia, Belsomra | $502 | $62,38762 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $66 | $38,51821 claims |
| Johnson & JohnsonXarelto | $461 | $34,83634 claims |
| NovartisEntresto | $111 | $22,11816 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $21 | $9,81816 claims |
| GSKBreo Ellipta | $77 | $7,10916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.